Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner
Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Figure 2: Phases of CML19

Phase Clinical Characteristics Median duration
Chronic phase < 15% blasts and promyelocytes in the peripheral blood and bone marrow 3-5 years
Accelerated phase > 15% to < 30% blasts in either the peripheral blood or bone marrow 6-18 months
Blastic phase > 30% blasts in the peripheral blood or bone marrow (some authors use this term interchangeably with "blast crisis") 3-6 months
Blast crisis > 30% blasts are present in the face of fever, malaise, and progressive splenomegaly; blast crisis is a subset of blast phase (some authors use this term interchangeably with "blastic phase")  
Relapse Any evidence of progression of disease from a stable remission, which may include increased myeloid or blast cells in the peripheral blood or bone marrow, cytogenetic positivity for BCR-ABL when previously cytogenetic negative, or FISH positivity for BCR-ABL when previously FISH negative. (Note that detection of BCR-ABL by RT-PCR during prolonged remissions does not constitute relapse on its own)  

Return to Document
Proceed to Figure 3

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care